Document:

EX-10.16 Amendment to Consulting Agreement

 

EXHIBIT 10.16

EXECUTION COPY

AMENDMENT TO CONSULTING AGREEMENT

This Amendment (“Amendment”) is made effective July 6, 2007 (“Effective Date”), by and between MAKO
Surgical Corp. (“MAKO”) with a principle place of business at 2555 Davie Road, Ft. Lauderdale, FL
33317 and Martin W. Roche, M.D. (“Consultant”) currently residing at 2320 Delmar Place, Ft.
Lauderdale, Florida 33301.

Recitals

Whereas, MAKO and Consultant have entered into that certain Consulting Agreement, dated
August 12, 2005 (the “Agreement,” the terms of which are expressly incorporated herein), whereby
MAKO engaged Consultant to employ his experience, knowledge and insights as an orthopaedic surgeon
to assist MAKO in the development of its orthopaedic medical devices and supplies, their use and
clinical application as well as in understanding the general state of the industry; and

Whereas, Consultant, as a qualified and experienced orthopaedic surgeon, duly licensed in
the state of Florida, has assisted MAKO in developing with knowledge and insight on an independent
contractor basis.

Whereas, following the Effective Date, Consultant and MAKO intend to enter into that
certain Development Agreement for development of the MAKO Modular Knee implant (the “Development
Agreement”

THEREFORE, in consideration of the mutual covenants, agreements, representations and warranties
contained in the Agreement and this Amendment, the parties hereby agree as follows:

1. Effect on the Agreement; Definitions. Except as may be expressly provided herein, all
terms and conditions set forth in the Agreement to which this Amendment applies, shall remain in
full force and effect. In the event of a conflict between this Amendment and the Agreement, this
Amendment shall be controlling. Unless otherwise defined herein, capitalized terms shall have the
same meaning as described in the Agreement.

2. Non-Competition Covenant. Section 7.1 of the Agreement entitled “Conflicting
Work” is hereby deleted in its entirety and replaced with the following language:

7.1 Conflicting Work.

     (a) From the Effective Date of the Agreement through, and continuing thereafter until
the end of the [***] following termination of the Agreement for whatever reason, Consultant
agrees not to (and Consultant agrees to cause its officers and members not to), in any
manner directly or indirectly engage (whether as principal, agent, investor, distributor,
representative, stockholder, or consultant or otherwise, with or without pay) in any
consulting, product development or similar activity or business venture anywhere in the
world that, in the reasonable discretion of Company, is related to either of the fields of
(i) MAKO Robotics or (ii) MAKO Navigation. provided, however, that the passive beneficial
ownership of less than one percent (1%) of the shares of stock of any
corporation having a class of equity securities actively traded on a national securities

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

					
	 	 	 	 	 
	Dr. M. Roche — Amendment to the Consulting Agreement
	 	 
	 	 

1

 

EXECUTION COPY

exchange or over-the-counter market shall not be deemed, in and of itself, to violate the
prohibitions of this section. Notwithstanding the foregoing, Consultant covenants,
represents and warrants that, during the term of this Agreement, he will not engage in any
work for others involving the same or similar subject matter as to which Consultant is
performing Services hereunder. Consultant further represents and warrants that he will not
enter into any agreement, arrangement or understanding that would conflict with this
Agreement or prevent Consultant from performing the Services hereunder during the Term of
this Agreement.

(b) For the purposes of this Section 7.1, “MAKO Robotics” shall be defined as
“human-interactive robotics within Orthopedics, “ which more specifically means any use of a
system (a) containing an electromechanical device or interface; (b) in or by which a user
(i) experiences tactile sensations and/or virtual constraints; (ii) interacts with a
computer by receiving tactile feedback (which feedback may be achieved by applying a degree
of opposing force to the user along the x, y, and z axes, or through any other means); or
(iii) grasps and/or operates any tool or device which is constrained in its operation by a
physical guide which itself is attached to an electromechanical device; and (c) used in
Orthopedics.

(c) For the purposes of this Section 7.1, “MAKO Navigation” shall be defined as image guided
surgery (IGS) and/or computer assisted surgery (CAS) either of which combines medical
imaging and computer technology into a system for surgery planning and navigation when
enabled by, bundled (on whole or in part) with and/or enhanced through the use of MAKO
Robotics.

(d) For the purposes of this Section 7.1, “Orthopedics” shall be defined as the
medical specialty concerned with the preservation, restoration, development, repair and
correction of the musculoskeletal system and associated structures, whereby, for avoidance
of doubt, products that may be used in Orthopedics shall include, but are not limited to,
the following: (a) reconstructive including orthopedic joint replacement, bone cements and
accessories, dental reconstructive products and platelet systems; (b) fixation products
including electrical bone growth stimulation, internal and external orthopedic fixation,
craniomaxillofacial devices and bone growth substitute materials; (c) spinal products
including spinal stimulation, spinal hardware, pain therapy, and orthobiologics; and
(d) arthroscopy, diagnostics, sofigoods, and bracing, provided however, that notwithstanding
the forgoing, the following medical specialties are, to the extent that they may otherwise
come within the scope of the definition given above, specifically excluded from Orthopedics:
(i) Non-bone oncology; (ii) Blood vessels and vital organs; (iii) Neurology, which is the
medical specialty concerned with the brain, spinal cord and nervous system and including
neurosurgery; and (iv) Cranial neurosurgery, ENT and Otolaryngology.

(e) Notwithstanding the negative covenants contained in this Section 7.1, nothing herein
shall be construed to constrain or otherwise limit the restrictions set forth in Section 5.1
of the Design Agreement, which shall be in addition to and separate from the restrictions
set forth herein.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

					
	 	 	 	 	 
	Dr. M. Roche — Amendment to the Consulting Agreement
	 	 
	 	 

2

 

EXECUTION COPY

(f) In consideration for the additional negative covenants contained in this Section 7.1, as
of the Effective Date, MAKO has granted to Consultant a grant of Nonqualified Stock Option
(NSO), issued pursuant and subject to the MAKO 2004 Stock Incentive Plan (the “Option
Plan”), entitling Consultant to purchase Ten Thousand (10,000) shares of the MAKO Common Stock (the “Option
Grant”). The per share purchase price for the NSO issued to Consultant shall be as
determined by an independent valuation company engaged by MAKO for such purpose, which shall
be the fair market value of such Common Stock at the time of this Option Grant. The Option
Grant shall be made pursuant and subject to the terms and conditions (including, without
limitation, terms and conditions pertaining to vesting) of the standard MAKO NSO Agreement
(with associated exhibits) between MAKO and Consultant, a copy of which has previously been
provided to Consultant.

3. Payment for Services. The following language shall be appended to Section 2.1 of the
Agreement, which shall otherwise remain unchanged:

In recognition of the enhanced fair market value of Services provided by Consultant (as one
of MAKO’s most tenured and publicly visible consultants), the Hourly Rate set forth on
Attachment A hereto shall be raised from time to time [***].

4. Fair Market Value for Restrictions and Services. The Parties acknowledge and agree that
the consideration paid under this Amendment is intended to be consistent with fair market value in
an arm’s length transaction and is not intended, directly or indirectly, to compensate Consultant
for ordering, using, or recommending MAKO’s products. If at any time during the Term, MAKO
determines reasonably and in good faith that any payment made or to be made under this Amendment or
the Agreement is no longer consistent with fair market value or maybe a violation of any applicable
law, regulation or industry guideline, then MAKO is not obligated to pay any amount higher than the
amount, if any, that MAKO reasonably and in good faith determines is permitted under such law,
regulation or industry guideline.

5. Counterparts; Facsimile Signatures. This Amendment may be executed in
counterparts, each of which are deemed to be original, but both of which together constitute one
and the same instrument. Copies of signatures sent by facsimile transmission are deemed to be
originals for purposes of execution and proof of this Amendment.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

					
	 	 	 	 	 
	Dr. M. Roche — Amendment to the Consulting Agreement
	 	 
	 	 

3

 

EXECUTION COPY

* * * * *

In Witness Whereof, the Parties have duly executed this Amendment to be effective as of
the date set forth above as the Effective Date.

	 	 	 	 	 	 	 	 	 	 	 
	MAKO Surgical Corp.	 	 	 	Martin W. Roche, M.D.
	2555 Davie Road	 	 	 	2320 Delmar Place,
	Ft. Lauderdale, Florida 33317	 	 	 	Ft. Lauderdale, Florida 33301
	 
	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Maurice R. Ferré	 	 	 	Signature:	 	 /s/ Martin Roche
	 	 	 	 	 	 	 	 	 
	Maurice R. Ferré M.D.	 	 	 	Title:	 	MD	 	 
	President & CEO	 	 	 	Soc. Sec. No.:	 	[***]
	Date:	 	7-6-07	 	 	 	Date:	 	7-6-07

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

					
	 	 	 	 	 
	Dr. M. Roche — Amendment to the Consulting Agreement
	 	 
	 	 

4EX-10.17 Development Agreement

 

EXHIBIT 10.17

EXECUTION COPY

Development Agreement

     This Development Agreement (“Agreement”), is made and entered into, to be effective as of July
6, 2007 (the “Effective Date”), by and between MAKO Surgical Corp, a Delaware corporation having
its principal place of business at 2555 Davie Road, Ft. Lauderdale, Florida (“Company”), and Martin
W. Roche, M.D., with an address at 2320 Delmar Place, Ft. Lauderdale, Florida 33301 (“Physician”).
Company and Physician may each be referred to individually as a “Party” and collectively as the
“Parties.”

RECITALS:

     WHEREAS, Company provides medical devices and related supplies and services used for
addressing joint disease;

     WHEREAS, Physician and Company have previously entered into that certain Consulting Agreement,
dated August 12, 2005 (as amended, the “Consulting Agreement”), whereby Physician agreed to provide
certain Services (as defined in the Consulting Agreement) for and on behalf of the Company;

     WHEREAS, pursuant to the terms of this Agreement, Physician intends to perform or has
performed certain services particular to development of the Invention (as defined below);

     WHEREAS, Physician desires to assign to Company all of Physician’s rights in and to the
Invention and all Intellectual Property Rights (as defined below) thereto;

     NOW, THEREFORE, in consideration of the mutual agreements, covenants, terms and conditions
herein contained, Company and Physician agree as follows:

Article 1

Definitions

Section 1.1 Affiliate “Affiliate” means, with respect to a specified person (natural or
juridical), a person that directly, or indirectly through one or more intermediaries, controls, or
is controlled by, or is under common control with, the person specified. “Control” means ownership
of more than fifty percent (50%) of the shares of stock entitled to vote for the election of
directors in the case of a corporation, and more than fifty percent (50%) of the voting power in
the case of a business entity other than a corporation.

Section 1.2 Change of Control “Change of Control” shall mean a transaction or the last of a
series of transactions that results in a person or entity obtaining Control of, directly or
indirectly, all or any substantial portion of the assets of Company.

Section 1.3 Control “Control” shall more direct the affairs of Company by the voting stock
of Company, or the reason of ownership or other control of 50.01% or acquisition of all or
substantially all of the assets of Company.

Section 1.4 Excluded Parties. “Excluded Parties” means, collectively: (i) any employee,
partner, member or shareholder in any medical practice of which the Physician is also an employee,

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

- 1 -

 

EXECUTION COPY

partner, member or shareholder (“Physician’s Practice”); (ii) any Physician or other health
professional employed by or associated with Physician’s Practice; and (iii) any hospital,
institution, medical facility or other entity at which Physician or any physician employed by or
associated with Physician’s Practice has privileges to perform orthopedic surgery. A list of all
Excluded Parties reasonably contemplated by Physician as of the Effective Date to be potential
customers of Royalty Products is attached as Exhibit A: Excluded Parties. For so long as
there shall be Royalties due to Physician, Physician covenants to provide the Company with written
updates to Exhibit A with both actual and contemplated potential customers as they become known to
Physician.

Section 1.5 Intellectual Property Rights. “Intellectual Property Rights” means any patent
and/or patent application related to the Invention and naming Physician as an inventor or
co-inventor, and including any and all U.S. and international patents issuing therefrom or claiming
priority thereto and any and all continuations, continuation-in-part, divisionals, reissues or
reexaminations based thereon or claiming priority thereto, and any and all know-how, technology and
any other intellectual property right with respect to the Invention. A listing of certain of the
Intellectual Property Rights is contained in Exhibit B: Intellectual Property Rights.

Section 1.6 Inventions. “Inventions” means any inventions, discoveries, improvements and
ideas (whether or not they are in writing or reduced to practice) and works of authorship (whether
or not they can be patented or copyrighted) that (i) the Physician makes, authors, or conceives
(either alone or with others) during the course of the Project, and (ii) relate in any way,
directly or indirectly, to the Medical Devices and/or instrumentation related to such Medical
Devices including, but not limited to, any improvements or modifications to such Medical Devices or
related instrumentation.

Section 1.7 Medical Device. “Medical Device(s)” means Company’s Modular Knee implant
device described in Exhibit C, but expressly excluding the DePuy [***] Project described in Exhibit C.

Section 1.8 Net Sales.

	 	(a)	 	“Net Sales” means, for a particular period, the amount that Company or its Affiliates
receives from third parties (excluding transactions between Company and its Affiliates)
during such period for commercial sales (excluding sales for use in clinical trials or
other testing purposes) of Royalty Products, less any of the following, as applicable,
which are incurred by Company or its Affiliates in connection with the sale of the Royalty
Products: (i) any refunds, credits or allowances actually given or credited to any party
due to rejections, defects or returns of the Royalty Products, (ii) any discounts or
rebates actually given or credited, (iii) sales commissions in the amount of [***] percent
([***]%), (iv) any administrative or marketing fees actually paid or credited to third
parties, (v) any sales, use, occupation or excise taxes, duties or other governmental
charges imposed on the production, importation, exportation, use or sale of a Royalty
Products, and (vi) any freight, postage or insurance charges.
	 
	 	(b)	 	If Company or its Affiliates sell at a single price or rate a medical device or
packaged combination of products, not all of which, if sold individually, would be a
“Royalty Product”, then “Net Sales” with respect to such sales of packaged products shall
equal the

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

- 2 -

 

EXECUTION COPY

	 	 	 	number of units of the Royalty Products sold as part of such packaged products
(less rejections, defects and returns) multiplied by (i) [***], or (ii), [***], in either
case less the amounts specified in Sections (a)(i) through (vi) above.
	 
	 	(c)	 	Notwithstanding the foregoing, “Net Sales” does not include sales of any Royalty
Products to any Excluded Party or any sales of any Royalty Products which are implanted or
used in (i) patients under the care and treatment of any Excluded Parties or (ii) patients
hospitalized at any hospital that is an Excluded Party.
	 
	 	(d)	 	For purposes of this definition, a Royalty Product is considered “sold” only on the
date that Company receives payment for the Royalty Product.

Section 1.9 Project. “Project” means the services to be performed by the parties under the
Description of Services attached as Exhibit D: Description of Services.

Section 1.10 Quarter. “Quarter” means a three month period commencing on January 1, April 1, July
1 or October 1.

Section 1.11 Royalty Product(s). “Royalty Product(s)” means one of the following, as applicable:

	 	(a)	 	a component of the Medical Devices that satisfies all of the following conditions:

	 	1.	 	such component, or instrumentation related to such component,
incorporates an Invention,
	 
	 	2.	 	Physician makes a significant innovative design contribution to such
component, or instrumentation related to such component, and
	 
	 	3.	 	the sole and exclusive ownership of Physician’s contribution to such
component, or instrumentation related to such component, is assigned to Company
under this Agreement.

	 	(b)	 	the Medical Devices, but only to the extent that

	 	1.	 	such Medical Devices, or instrumentation related to such Medical
Devices, incorporate the Invention,
	 
	 	2.	 	Physician makes a significant innovative design contribution to such
Medical Devices or instrumentation related to such Medical Devices, and
	 
	 	3.	 	the sole and exclusive ownership of such Medical Devices and
instrumentation related to such Medical Devices is assigned to Company pursuant to
this Agreement.

A Physician shall be deemed to have made a significant innovative design contribution to the
development of a component or instrumentation or Medical Device if and only if such Physician

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

- 3 -

 

EXECUTION COPY

would
be required under applicable law to be named as an inventor or co-inventor in a United States
patent application on such component or instrumentation, or Medical Device.

Royalty Products are listed by catalog number in Exhibit E: Royalty Products, at such time
as catalog numbers are available, pursuant to Section 3.2. Royalty Products shall include
only the items listed in Exhibit E: Royalty Products from time to time during the term of
this Agreement. Company may amend Exhibit E: Royalty Products from time to time with
written notification to Physician to update the various components to be included as Royalty
Products. “Royalty Products” do not include any product, invention or device for which Physician
is paid a royalty by Company, or any Affiliate of Company, under any other agreement entered into
by Physician with Company or any Affiliate of Company.

Article 2

Services

Section 2.1 General. Physician shall perform the services (“Services”) described in
Exhibit D: Description of Services and work diligently to develop the Invention(s) and meet
the milestones (“Milestones”) described in Exhibit G: Development Timeline in accordance
with the time frames set forth therein.

Section 2.2
Management. If at any time either party desires a change in the provision of
Services or Inventions, such party shall submit to the other a written proposal specifying the
desired changes (“Change Request”). In the event of a Company Change Request, Physician will
submit to Company a written response to each such Change Request within ten (10) working days,
which will include any impact the proposed changes will have on Exhibit D: Description of
Services, Exhibit G: Development Timeline or the fees and/or royalty payments (“Change
Response”). If Physician submits a Change Request to Company, such Change Request shall include
the information required for a Change Response.

Section 2.3 Project Delays. Physician will inform Company as early as possible of any
anticipated delays in meeting the timeframes and of the actions being taken to assure completion of
the Services and Inventions within a time period acceptable to Company.

Section 2.4 Meetings and Reports. The Parties shall meet at a site designated by Company
or by teleconference every month (or more or less frequently upon mutual agreement), to discuss the
progress of the Project and Physician’s progress in meeting the Milestones. Approximately every
two weeks, unless otherwise mutually agreed, Physician agrees to present to Company a written
status report of the Project and its progress, on a task-by-task basis, including, without
limitation, Physician hours expended, budget and schedule and any impediments to the timely
completion of the Project, all sufficiently in advance to permit Company to compensate for or to
overcome or work around such impediment. Company will provide a written update of minutes and
designs prior and after meetings. Company shall provide Physician with supplies and equipment
reasonably necessary to participate in such meetings, which may include, at Company’s discretion
with input from Physician, a secure website by which Physician could review engineering models and
web based cameras to allow for remote communications.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

- 4 -

 

EXECUTION COPY

Section 2.5 Acceptance. Unless otherwise agreed, Company shall have a minimum of thirty
(30) calendar days from the date the proposed deliverables or models of the Inventions are
delivered to Company in order to review and test such items to ensure they are and/or perform
satisfactorily. Company shall notify Physician in writing of the existence of any defect in the
items and Physician shall, at no additional cost to Company, work diligently to correct such
defect. After Company is satisfied that the Deliverables (as corrected, if applicable) contain no
defects and that they are and/or perform satisfactorily, Company shall provide Physician with a
written notice of acceptance. “Acceptance” shall be deemed to occur on the date of such notice.
No other event shall constitute legal acceptance of any Deliverable under contract law or the
Uniform Commercial Code.

Section 2.6 Other Services. In addition, during the term of this Agreement, Physician
shall provide such technical skills and services to Company, in connection with the development,
clinical evaluation, marketing and promotion of the Royalty Products and other Company medical
devices, as may be requested by Company, including, but not limited to, the following: providing
input to Company on the design and development of the Royalty Products and related instruments,
providing clinical evaluations of the Royalty Products and related instruments, preparing and
authoring surgical techniques and peer review articles, attending seminars, shows, conventions and
the like, conducting presentations and demonstrations of the Royalty Products, and developing
advancements, improvements and/or modifications of the Royalty Products. In addition, Physician
shall provide Company with preclinical and clinical input, evaluation, support, and assistance in
connection with clinical trials related to the development of the Royalty Products. Physician
shall make himself available to provide such services from time to time as reasonably requested by
Company. Company shall reimburse Physician for reasonable expenses of travel, lodging, daily meals
and other necessary and reasonable expenses incurred in the performance of the services described
in this Section 2.6, provided that such expenses are supported by original receipts and
other supporting documentation and that advance authorization is obtained from Company prior to
incurring any such expenses.

Section 2.7 Consulting Agreement. The Services to be rendered pursuant to this Agreement
shall be in addition to and separate from those Services to be rendered by Physician pursuant to
the Consulting Agreement. Physician shall be compensated for Services provided hereunder only in
accordance with the terms of this Agreement, it being the expressed intention and understanding of
the Parties that Physician shall not be doubly compensated for Services under both this Agreement
and the Consulting Agreement, but rather Physician shall be compensated only based on the terms of
the applicable agreement. All other terms set forth in this Agreement shall be deemed to
compliment those set forth in the Consulting Agreement, unless such terms directly conflict, in
which case the terms of the applicable agreement shall control.

Article 3

Proprietary Rights

Section 3.1 Proprietary Rights. As between Physician and Company, Physician agrees that
all Inventions and portions thereof, and all intermediate and partial versions thereof, including
without limitation all artwork, images, reports, documentation, databases, computer programs,
materials, charts, notes, and outlines and all derivatives, in any and all media, (the “Work
Product”) are owned by Company. Such ownership shall inure to the benefit of Company from the date
of

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

- 5 -

 

EXECUTION COPY

the conception, creation or fixation of the Work Product in a tangible medium of expression, as
applicable. Company and Physician agree that, as applicable, all copyright aspects of the Work
Product shall be considered a “work-made-for-hire” within the meaning of the Copyright Act of 1976,
as amended. If and to the extent the Work Product, or any part thereof, is found by a court of
competent jurisdiction not to be a “work-made-for-hire” within the meaning of the Copyright Act of
1976, as amended, Physician expressly assigns to Company all exclusive right, title and interest in
and to the copyright, patent, trademark, trade secret and all other proprietary rights in and to
the Work Product without further consideration, free from any claim, lien for balance due or rights
or retention thereto on the part of Physician. Physician agrees to execute all documents that may,
in Company’s sole discretion, be required to perfect such assignment.

Section 3.2 Assignment. Physician hereby agrees to transfer and assign to Company or its
designee, and does hereby transfer and assign to Company or its designee, all of Physician’s right,
title and interest in and to all Inventions and Intellectual Property Rights. Physician
acknowledges that Company or its Affiliates may, at their sole discretion and expense, apply for
patents, trademarks and/or copyrights on such Inventions. Physician will execute and deliver to
Company the form of Assignment attached hereto as Exhibit F: Form of Assignment (the
“Assignment”), and sign such other documents and take such other actions as Company may request,
without further compensation, to assist Company, or its designee, in establishing title to such
Inventions and Intellectual Property Rights or to obtain and enforce patent protection thereon.
Royalties will be paid for a Royalty Product only after receipt by
Company of an Assignment(s) for
the applicable Invention(s). Upon receipt of an Assignment from Physician, Company will include
any applicable Royalty Products on Exhibit E: Royalty Products, at such time as the
applicable catalog numbers are available.

Article 4

Royalty Payments

Section 4.1 Fees for Services.

	 	(a)	 	Company shall pay to Physician fees for Services in the amount set forth in Exhibit
D: Description of Services (“Service Fees”). In no event will Company pay more than
fair market value for the Services performed by Physician. The Parties agree that the
Service Fees are a good faith estimate of the fair market value of the Services to be
performed by Physician, and, if, during performance of the Services, in Company’s good
faith opinion, the agreed-upon fees for Services exceed the fair market value of the
Services, the Parties shall negotiate in good faith to reduce the fees for Services to be
at fair market value or, in the event the parties do not agree, Company may terminate the
Agreement immediately with no further obligation by either party to the other. Physician
agrees to keep accurate written records sufficient in detail to enable Company to determine
and verify the fair market value of the Services. Such records for a particular Quarter
shall be retained by Physician for a period of not less than one calendar year after the
end of such Quarter. Company shall have the right, at its own expense and on a
confidential basis to have an independent certified public accountant reasonably acceptable
to Physician review such records, at Physician’s offices upon reasonable notice and during
reasonable business hours, for the purposes of verifying royalties payable to Physician
hereunder. Such accountant shall execute a suitable

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

- 6 -

 

EXECUTION COPY

	 	 	 	confidentiality agreement reasonably acceptable to Physician prior to conducting such
audit. Such accountant may disclose to Company only its conclusions regarding the
accuracy and completeness of royalty payments and of records related thereto, and shall
not disclose Physician’s confidential information to Company without the prior written
consent of Physician. All Service Fees shall be Milestone — based. Physician shall
submit appropriate documentation demonstrating that it has achieved a particular
Milestone.
	 
	 	(b)	 	The Design Service Fees (as described in Exhibit D) shall be discounted by the Deferred
Amount (as set forth in Exhibit D), and paid pursuant to Section 4.4 below. The total of
all Deferred Amounts the Company is or shall become obligated to pay Physician shall be
referred to as the “Deferred Aggregate.”

Section 4.2 Royalty Products. Company shall pay, or cause an Affiliate of Company to pay,
to Physician royalty payments as follows (“Royalty Fees”):

	 	(a)	 	if the Royalty Product is not covered by a valid claim of an issued U.S. patent arising
out of the Intellectual Property Rights, a royalty payment in the amount of [***] percent
([***]%) of the Net Sales of the Royalty Product for a period of [***] from the date of
first commercial sale of the Royalty Product (“Royalty”); or
	 
	 	(b)	 	if the Royalty Product is covered by a valid claim of an issued U.S. patent arising out
of the Intellectual Property Rights, a royalty in the amount of [***] percent ([***]%) of
the Net Sales of the Medical Device for [***] (“Royalty”).

Section 4.3 Third Party Royalties. Should the Company be required to pay other third
parties a royalty to allow Company to market and sell the Royalty Product, Company agrees that
Royalty Fees payable to Physician shall not be reduced.

Section 4.4 Payment Terms.

	 	(a)	 	All payments by Company to Physician for Service Fees are due and payable within sixty
(60) calendar days after the receipt by Company of an undisputed invoice.
	 
	 	(b)	 	Within sixty (60) days after the end of each Quarter, Company shall provide Physician
with a written report indicating the amount of Net Sales of Royalty Products during such
Quarter and the amount of royalties due to Physician for such Quarter. Simultaneously with
making such report, Company shall pay to Physician the amount of fees due pursuant to
Section 4.2. No Royalty Fees will be made unless Physician updates Exhibit A:
Excluded Parties on an annual basis or as otherwise needed.
	 
	 	(c)	 	Upon the first commercial sale of any Royalty Product Physician’s right in and
entitlement to the Deferred Aggregate shall be forever waived and forgiven, and Physician
agrees to execute any instrument or document reasonably required by Company to evidence
such waiver and forgiveness.
	 
	 	(d)	 	If the first commercial sale of any Royalty Product has not occurred on or before (i)
the second (2nd) anniversary of a Change of Control occurring within one (1) year of

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

- 7 -

 

EXECUTION COPY

	 	 	 	the Effective Date or (ii) the first (1st) anniversary of a Change of Control occurring
after the second (2nd) anniversary of the Effective Date, whichever applies, then Company
shall pay the Deferred Aggregate to Physician within forty five (45) calendar days after the
receipt Physician’s written demand for the same.

Section 4.5 No Multiple Royalties. Company shall pay only one Royalty Fee on the Net Sale
of any Royalty Product, regardless of how many patents may cover such Royalty Product. Further, no
Royalty Fee will be paid hereunder on any component, item or device which is not a Royalty Product,
even if any Royalty Products are sold by Company as a part of a larger assembly or system.

Section 4.6 Records on Royalties. Company agrees to keep accurate written records
sufficient in detail to enable Physician to determine and verify the royalties payable by Company
under Section 4. Such records for a particular Quarter shall be retained by Company for a
period of not less than one calendar year after the end of such Quarter. Physician shall have the
right annually at his own expense and on a confidential basis to have an independent certified
public accountant reasonably acceptable to Company review such records, at Company’s offices upon
reasonable notice and during reasonable business hours, for the purposes of verifying royalties
payable to Physician hereunder. Such accountant shall execute a suitable confidentiality agreement
reasonably acceptable to Company prior to conducting such audit. Such accountant may disclose to
Physician only its conclusions regarding the accuracy and completeness of royalty payments and of
records related thereto, and shall not disclose Company’s confidential business information to
Physician without the prior written consent of Company.

Article 5

Non-Competition; Confidentiality

Section 5.1 Non-Competition. From the Effective Date through, and continuing thereafter
until the later of (i) the end of the first year in which Company owes no royalties pursuant to
Section 4 above and (ii) the termination of this Agreement, Physician agrees not to (and
Physician agrees to cause its officers and members not to), in any manner directly or indirectly:

	 	(a)	 	engage (whether as principal, agent, investor, distributor, representative,
stockholder, or consultant or otherwise, with or without pay) in any consulting, product
development or similar activity or business venture anywhere in the world related to a
product that, in the reasonable discretion of Company, is similar to or competitive with
any of the Royalty Products or any other product of Company or its Affiliates; for the
avoidance of doubt, products resulting from Physician’s rendition of any of the design
services under the DePuy Project described in Exhibit C hereto shall not be deemed
competitive for the purposes of this Section 5.1; or
	 
	 	(b)	 	solicit or entice or endeavor to solicit or entice away from Company any person who was
a director, officer, employee, agent or physician of Company, either on Physician’s or
Physician’s own account or for any third party, whether or not such person would commit any
breach of his/her contract of employment by reason of leaving the service of Company, and
each Physician agrees not to employ, directly or indirectly, any person who was a director,
officer or employee of Company or who by reason of such position at any time is

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

- 8 -

 

EXECUTION COPY

	 	 	 	or may be likely to be in possession of any Confidential Information relating to Company; or
(c) take any action or make any statement the effect of which would be, directly or
indirectly, to impair the good will of Company or the business reputation or good name of
Company, or be otherwise detrimental to Company, including any action or statement intended,
directly or indirectly, to benefit a competitor of Company.

The Parties agree that if, in any proceeding, the court or other authority shall refuse to enforce
the covenants herein set forth because such covenants cover too extensive a geographic area or too
long a period of time, any such covenant shall be deemed appropriately amended and modified in
keeping with the intention of the Parties to the maximum extent permitted by law.

Section 5.2 Confidentiality. Any information acquired by Physician from Company, including
the terms of this Agreement, and any material, information, data and devices developed in the
course of performing the activities described in this Agreement (“Confidential Information”),
including the Inventions, are or shall be the property of Company and shall be maintained in strict
confidence and not disclosed to any third party or used by Physician or any of Physician’s
employees, agents, or assistants, except as necessary to perform the activities described in this
Agreement. This provision will not apply to Confidential Information: (a) after it becomes
publicly available through no fault of the Physician; (b) which is later released by Company in
writing; or (c) which is lawfully obtained from third parties without restriction. All of a
party’s Confidential Information disclosed to the other party, and all copies thereof, shall be and
remain the property of the disclosing party. Upon the expiration or earlier termination of this
Agreement, or at any other time that Company so requests, Physician shall return to Company all
Confidential Information, as well as all copies, adaptations and independent compilations thereof
in Physician’s possession, or destroy the same at Company’s direction.

Article 6

Infringement

Company shall, at its sole discretion, cost and expense, defend any and all claims of infringement
that may be brought by third parties against it as a result of the sale of Royalty Products.
Company shall, at its sole discretion, cost and expense, prosecute patent infringement claims
against any and all third parties who manufacture, sell, or otherwise use products which constitute
an infringement of any intellectual property rights relating to Royalty Products and/or any patent
issued with respect to Royalty Products. Company and Physician shall immediately notify the other
in writing of any activity, of any type or nature whatsoever, which
the party believes to be an
infringement of Company’s intellectual property rights relating to Royalty Products. If Company
elects to prosecute such alleged infringement, Company shall be solely responsible for payment of
all of its own costs of prosecution and of negotiating settlement and shall retain all proceeds
from such prosecution. The parties shall cooperate with each other (including, without limitation,
joining in any litigation, if requested to do so) in all matters concerning any such infringement.
Physician shall cooperate in connection with the initiation and prosecution by Company of such
suit.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

- 9 -

 

EXECUTION COPY

Article 7

Term and Termination; Limitations

Section 7.1 Termination by Company. Company may terminate this Agreement by delivering
written notice thereof to Physician if (i) Physician breaches any of his material obligations as
set forth herein, provided that Physician shall have received written notice of such breach from
Company and have failed to correct such breach within thirty (30) days after such notice; or (ii)
Physician commits an act of fraud, theft or malfeasance against Company, or (iii) upon any material
adverse changes in Physician’s reputation within the medical community. If this Agreement is
terminated by Company pursuant to this section, then (i) Physician shall be entitled to all royalty
payments hereunder that shall have been paid to or accrued for Physician through the date of such
termination, and (ii) Company shall be relieved of any obligation to make any further royalty or
other payments provided for hereunder. The foregoing shall not be deemed to constitute a waiver of
any claims or rights that Company may have against Physician, and, in addition to the foregoing,
Company shall have all other rights and remedies available at law or in equity.

Section 7.2 Termination by Physician. If the first commercial sale of any Royalty Product
has not occurred on or before (i) the Second (2nd) anniversary of a Change of Control, or (ii) the
First (1st) anniversary of a Change of Control occurring after the
Second (2nd) anniversary of
the Effective Date, whichever applies, Physician may, upon written notice effective immediately,
terminate this Agreement.

Section 7.3 Limitation of Liability. IN NO EVENT SHALL COMPANY’S AGGREGATE LIABILITY
HEREUNDER, BASED ON ANY THEORY OF LIABILITY OR CAUSE OF ACTION, EXCEED THE TOTAL AMOUNT OF FEES
PAID BY COMPANY TO PHYSICIAN UNDER THIS AGREEMENT DURING THE TWELVE (12) MONTHS PRIOR TO THE EVENT
GIVING RISE TO SUCH CAUSE OF ACTION. IN NO EVENT SHALL COMPANY BE LIABLE FOR ANY INDIRECT, SPECIAL
OR CONSEQUENTIAL DAMAGES, INCLUDING BUT NOT LIMITED TO LOST PROFITS, SAVINGS OR REVENUE, EVEN IF
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

Article 8

Representations and Warranties

Section 8.1 Physician Warranties. Physician represents and warrants that: (a) he shall
perform the Services in a timely, competent and workmanlike manner and that the Invention will
perform as described in the Exhibit D: Description of Services; (b) he has and full
authority to provide the Inventions to Company hereunder; (c) neither the execution nor delivery of
this Agreement nor the carrying on of the Company’s business by the directors and officers of the
Company, nor the conduct of the Services as proposed, will conflict with or result in a breach of
the terms, conditions or provisions of, or constitute a default under, any contract, covenant or
instrument under which Physician is now obligated; (d) the Invention does not and will not infringe
upon and are free from any claim by any third party of infringement of any patent, trademark,
copyright, trade secret or any other proprietary right of any third party; and (e) the Invention
will be developed and provided in compliance with the requirements of all applicable federal, state
and local laws, ordinances, regulations and codes.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

- 10 -

 

EXECUTION COPY

Section 8.2
Mutual Warranties. Each party represents and warrants to the other that: (a)
it is organized and validly existing under the laws of the state of its incorporation and has full
corporate power and authority to enter into this Agreement and to carry out the provisions hereof;
(b) it is duly authorized to execute and deliver this Agreement and to perform its obligations
hereunder; (c) this Agreement is a legal and valid obligation binding upon it and enforceable
according to its terms; (d) the execution, delivery and
performance of this Agreement by such party
does not conflict with any agreement, instrument or understanding, oral or written, to which it is
a party or by which it may be bound and (e) comply with all applicable laws and rules including the
federal health care program anti-kickback statutes and the MAKO and AdvaMed Business Conduct
Standards.

Article 9

Indemnity

Physician shall indemnify and hold Company harmless from any and all claims, demands, losses,
damages, suits, judgments, penalties and liabilities, of any kind and nature whatsoever, including
payment of reasonable attorneys’ fees, based upon a material breach by Physician of this Agreement
or upon any negligent or wrongful act of Physician which may arise, directly or indirectly, from or
in connection with, their performance of the terms and conditions of this Agreement. Company shall
indemnify and hold Physician harmless from any and all claims, demands, losses, damages, suits,
judgments, penalties and liabilities, of any kind and nature whatsoever, including payment of
reasonable attorneys’ fees, based upon a material breach by Company of this Agreement or upon any
negligent or wrongful act of Company which may arise, directly or indirectly, from or in connection
with, its performance of the terms and conditions of this Agreement. Company does not carry any
general liability insurance which insures Physician against medical malpractice. Physician shall
provide such medical malpractice insurance at his own expense.

Article 10

Legal Requirements

If Company requires that this Agreement or any document relating to the subject matter hereof to be
legalized and/or notarized, or submitted, filed or registered with any government agency, Physician
agrees to assist in complying with those requirements. Any such submission, filing or registration
shall be made in the name and for the benefit of Company and shall be at the expense of Company.

Article 11

Miscellaneous

Section 11.1 Regulatory Approvals. The Inventor is responsible for seeking and securing
any necessary approvals or acknowledgements to fulfill his obligations hereunder.

Section 11.2 Independent Contractor. The parties are independent contractors of each other
and Physician is not entitled to privileges, services, facilities and benefits that are available
to Company employees.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

- 11 -

 

EXECUTION COPY

Section 11.3 Entire Agreement. This Agreement, including all Attachments specifically
mentioned, constitutes the entire understanding between the Parties relating to the subject matter
of this Agreement, and supersedes all prior or contemporaneous discussions, representations,
correspondence and agreements, oral or written, between the Parties not embodied herein.

Section 11.4 Amendments; Waiver. No amendments, changes, extensions or modifications to
this Agreement are valid and binding except if in writing and signed by the Parties. Waiver by
either Party of a breach or violation of any provision of this Agreement shall not operate as, or
be construed to be, a waiver of any prior, concurrent or subsequent breach. None of the provisions
of this Agreement are considered waived by either Party except when such waiver is given in
writing.

Section 11.5 Governing Law; Jurisdiction; Venue. This Agreement will be construed and
interpreted under and in accordance with the substantive laws of the State of Florida, without
regard to conflicts of law principles. Any action or proceeding arising under or relating to this
Agreement will be brought only in the courts of the State of Florida, County of Broward, or, if it
has or can acquire jurisdiction, in the United States District Court for the Southern District of
Florida, and each of the Parties consents to the exclusive jurisdiction of such courts (and the
appropriate appellate courts) in any such action or proceeding and waives any objection to venue
laid therein. Process in any action or proceeding referred to in the preceding sentence may be
served on either Party anywhere in the world.

Section 11.6 Notice. Any notices required in this Agreement shall be in writing, shall be
delivered in one of the following ways and deemed to have been received (a) on the date delivered
if delivered by hand, (b) the next following business day after being sent if sent by Federal
Express or other similar overnight courier, or (c) three (3) business days after mailing, postage
prepaid, by certified mail, return receipt requested, to the Party entitled to notice at the
addresses set forth in the preamble paragraph, or such other addresses as may be designated by
notice given hereafter.

Section 11.7 Severability. In the event that any provision contained herein is held to be
invalid or unenforceable, all other provisions of this Agreement are deemed severable and will
remain enforceable to the full extent permitted by law.

Section 11.8 Counterparts; Facsimile Signatures. This Agreement may be executed in two
counterparts, each of which are deemed an original, but both of which together constitute one and
the same instrument. Copies of signatures sent by facsimile transmission are deemed to be
originals for purposes of execution and proof of this Agreement.

Section 11.9 Survival of Obligations. All of the representations and warranties, and all
terms and provisions hereof intended to be observed and performed by the parties after the
termination or expiration of this Agreement, including, but not limited to, obligations under
Sections 1, 3, 5, 6, 7, 8, 9, 10 and 11, shall survive such termination or expiration and continue
thereafter in full force and effect, subject to applicable statutes of limitations.

Section 11.10 Successors and Assigns. This Agreement shall be binding upon and inure to
the benefit of the Parties hereto and the successors or permitted assigns of the parties hereto.
The rights and obligations of Physician herein may not be assigned, and the rights and obligations
of

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

- 12 -

 

EXECUTION COPY

Company maybe assigned to any Affiliate of Company or to any successor of all or substantially all
of the business and assets of Company to which this Agreement relates.

Section 11.11 Titles and Headings; Construction. Titles and headings to Sections herein
are inserted for the convenience of reference only and are not intended to be a part of or to
affect the meaning or interpretation of this Agreement. This Agreement shall be construed without
regard to any presumption or other rule requiring construction hereof against the party causing
this Agreement to be drafted.

Section 11.12 Benefit. Nothing in this Agreement, expressed or implied, is intended to
confer on any person other than the parties hereto or their respective successors or assigns, any
rights, remedies, obligations or liabilities under or by reason of this Agreement.

Section 11.13.
Notices. All notices or other communications to a party required or
permitted hereunder shall be in writing and shall be delivered personally or by facsimile (receipt
confirmed electronically) to such party (or, in the case of an entity, to an executive officer of
such party) or shall be sent by a reputable express delivery service or by certified mail, postage
prepaid with return receipt requested, addressed as follows:

if to Company to:

MAKO Surgical Corp.

2555 Davie Road

Ft. Lauderdale, Florida 33317

Telephone: 954-927-2044

Facsimile: 954-927-0446

Attention: General Counsel

if to Physician to:

Martin W. Roche, M.D.

2320 Delmar Place

Ft. Lauderdale, Florida 33301

Any party may change the above-specified recipient and/or mailing address by notice to all other
parties given in the manner herein prescribed. All notices shall be deemed given on the day when
actually delivered as provided above (if delivered personally or by facsimile, provided that any
such facsimile is received during regular business hours at the recipient’s location) or on the day
shown on the return receipt (if delivered by mail or delivery service).

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

- 13 -

 

EXECUTION COPY

     IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the date set forth
below and effective as of the Effective Date.

	 	 	 	 	 	 	 	 	 	 	 
	MAKO SURGICAL CORP.	 	 	 	PHYSICIAN	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Maurice R.Ferré
 

	 	 	 	By:
	 	 /s/ Martin Roche, M.D.
 

	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Title:

	 	President/CEO
	 	 	 	Date:
	 	7/6/07	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Date:	 	7/6/07	 	 	 	If U.S. payee, tax identification is required:	 	 
	 	 	 	 	 	 	FEIN or SS#: [***]	 	 

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

- 14 -

 

EXHIBIT A

M.
Roche Excluded Parties

[provisional
— to be updated from time to time]

	 	•	 	Holy Cross Hospital

	 	•	 	Holy Cross Orthopedic Institute

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

 

 

EXHIBIT B

Intellectual Property Rights

[To be completed]

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

 

 

EXHIBIT C

Description of Medical Device: MAKO Modular Knee

The MAKO Modular Knee is a system designed to enable the surgeon to address various stages of
arthritic disease. The implant components are segmented into medial, lateral, and patellofemoral
compartments, and the anatomic resurfacing design minimizes bone removal, preserving both the ACL
and PCL. This enables the surgeon to replace only the compartments of the knee that are affected
by disease, such as single, bicompartmental, or tricompartmental, which maximizes the retention of
healthy bone and tissue. Because the three compartments are segmented, the individual components
are much smaller than a single tricompartmental monolithic component. Therefore, the MAKO Modular
Knee components can be implanted through a 1-2” incision. The implant bone preparation is
accomplished through the use of the MAKO Haptic Guided SystemTM (HGS) and accompanying modular
system instrumentation. The MAKO HGS is a unique haptic robotic system and application software
that enables the surgeon to perform preoperative planning and to accurately prepare the bone
infra-operatively through a small incision.

The Medical Device: MAKO Modular Knee shall expressly exclude the following orthopedic implant
fields, within which Physician is providing exclusive design services for DePuy Orthopedics (the “DePuy Project”):

(a) Design services relating to any [***] (including related instrumentations and surgical
processes and techniques).

(b) Design services relating to any [***] (including related instrumentations and surgical
processes and techniques) addressing the [***] of the knee joint through a [***] designed to cover
[***] with [***] and a [***] designed to cover [***] with a [***].

(c) Design services relating to a [***] through the use of [***] surgery ([***]) and/or [***]
surgery ([***]) either of which combines [***] and [***] into a system for surgery planning and
[***] (collectively, “[***]”).

provided, however, that services described in (a), (b) and (c), above, shall be excluded from the
DePuy Project to the extent the such services are rendered in the following fields exclusive to MAKO:

(1) the field of Robotics defined as “human-interactive robotics within orthopedics,” which more
specifically means any use of a system (a) containing an electromechanical device or interface;

(b) in or by which a user (i) experiences tactile sensations and/or virtual constraints; (ii)
interacts with a computer by receiving tactile feedback (which feedback may be achieved by applying
a degree of opposing force to the user along the x, y, and z axes, or through any other means);
(iii) grasps and/or operates any tool or device which is constrained in its operation by a physical
guide which itself is attached to an electromechanical device; or (iv) grasps and/or operates any

(2) in the field of orthopedic implants enabled and/or delivered through the use of Robotics;

(3) in the field of Surgical Navigation when enabled by, bundled (in whole or in part) with and/or
enhanced through the use of Robotics.

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

 

EXHIBIT D

Description of Services

[Provisional Services — SUBJECT TO REVISION]

	 	•	 	Attend Design Advisory Board (DAB) Meetings (frequency to be determined by consensus
among DAB and MAKO employees (together, the MMK Program Team)), including annual MAKO Modular Knee
(MMK) DAB Review Meeting (2 Days)

	 	o	 	Attend DAB Kick Off in [***] and materially collaborate in providing the following contemplated
deliverables

	 	•	 	MMK [***] Requirement Specification and [***] Indications
	 
	 	•	 	[***] technique concepts
	 
	 	•	 	Design inputs on [***] configurations and provide data as
	 
	 	•	 	necessary for design requirements

	 	•	 	Materially collaborate on all DAB Output including, but not limited to:

	 	o	 	Meet with MMK Program Team on a regular basis [***]. Frequency likely to be at [***].
	 
	 	o	 	Execute [***] and [***] labs to test and validate [***] with the HGS platform and to
develop [***] technique
	 
	 	o	 	Participate in the development of the [***] technique document — permission to use name
and sign-off
	 
	 	o	 	Help to develop and sign-off on “[***]” planning that will be [***] with respect to the
[***] design.
	 
	 	o	 	Provide consultation as required around [***]
	 
	 	o	 	Execute first [***] with MMK and collect and report data as required
	 
	 	o	 	Join [***] Study
	 
	 	o	 	In collaboration with [***], define, execute and publish [***]
	 
	 	o	 	As required, support the development of and delivery of [***] programs for surgeons, staff
and MAKO personal in the [***]
	 
	 	o	 	As required, attend MAKO [***] events. An example of this would be speaking on [***] MMK
in MAKO [***] (or other venue) during [***]

Service Fees:

	 	•	 	Design Service Fees: Physician shall perform the Services listed in this Exhibit D at an
hourly rate of [***] Dollars ($[***]) per hour, provided however that [***] Dollars
($[***]) of Physician’s hourly rate will be deferred (as to each hour of Services
performed, the “Deferred Amount”), and payable only pursuant to Section 4.4 of the
Agreement.
	 
	 	•	 	Travel Service Fees: Physician shall be compensated for actual travel time associated
with providing Services at an hourly rate of [***] Dollars ($[***]), which shall not be
subject to deferral but in any case shall be capped for any [***] period at [***] ([***])
hours.

 
 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

 

 

EXHIBIT E

Royalty Products

[To be completed]

 
 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

 

 

EXHIBIT F

Form of Assignment

[To be completed]

 
 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

 

 

EXHIBIT G

Project Timeline

[Provisional Milestones — SUBJECT TO REVISION]

	 	•	 	Background / Setup [***] 2006 — [***] 2007 
	 
	 	•	 	Design & Development [***] 2007 — [***] 2007 

	 	•	 	[***] Testing 
	 
	 	•	 	[***] Testing 

	 	•	 	Design [***] / [***] [***] 2007 — [***] 2007 
	 
	 	•	 	[***] Production Build [***] 2007 — [***] 
	 
	 	•	 	[***] (FDA) Testing [***] 2007 — [***] 
	 
	 	•	 	[***] Demonstration [***] 2007 
	 
	 	•	 	[***] Sub/Clear — [***] [***] — [***] 
	 
	 	•	 	[***] Sub/Clear — [***] [***] — [***] 
	 
	 	•	 	[***] Sub/Clear — [***] [***] — [***] 
	 
	 	•	 	[***] Production [***] — [***]
	 
	 	•	 	[***] Surgery [***]
	 
	 	•	 	[***] Surgery [***]

 

 

			
	[***]	 	Confidential treatment has been requested for portions of this exhibit.
The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [***]. A complete version of this exhibit has been filed separately with the Securities
and Exchange Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}]]